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An antithrombin III variant was identified in the plasma of a female patient with a history of recurrent hromboses. 
The variant was shown to have normal antigenic levels but reduced heparin and progressive inhibitory activity consistent 
with an abnormality affecting function at the reactive centre. Polymerase chain reaction amplification of exon 6 of the 
gene with direct sequencing showed a point mutation resulting in the substitution of a proline for alanine at position 
384. This substitution will predictably alter the conformation of the peptide loop containing the reactive centre of the 
molecule. 
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1. INTRODUCTION 
Human antithrombin III (ATIII) is a single- 
chain 432 amino acid glycoprotein of molecular 
weight 58000. It is a member of the serpin super- 
family and is the major inhibitor of a number of 
serine proteases in the coagulation pathway in- 
cluding thrombin [ 1,2]. Under normal physiologi- 
cal conditions this inhibition is relatively slow but 
in the presence of heparin, it s greatly accelerated 
[3]. Its importance as an inhibitor is emphasised by 
the recurrent thromboses that occur in individuals 
with abnormal or deficient ATIII. 
We describe here a new variant, with defective 
protease inhibitory activity but normal heparin 
binding and in which the underlying genetic muta- 
tion was established by means of the polymerase 
chain reaction (PCR) [4]. 
2. MATERIALS AND METHODS 
2.1. Materials 
All reagents were obtained from Sigma unless otherwise 
stated. Deoxynucleotides and Sephadex Cl00 were obtained 
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from Pharmacia-LKB Biotechnology, Thermus aquaticus (Taq) 
polymerase from Perkin Elmer Cetus, and Ultrapure agarose 
from Gibco-BRL. DNA sequencing used Sequenase version 2.0 
(modified T7 DNA polymerase) were obtained from the US Bio- 
them. Corp. Chromogenic substrate Chromozym TH was ob- 
tained from Boehringer Mannheim and S2222 from Kabi 
Diagnostica. 
2.2. Antithrombin measurements in plasma 
Antithrombin antigen was measured by competitive ELISA. 
Antithrombin anti-IIa activity was measured in the absence (an- 
tithrombin progressive activity) or in the presence of heparin 
(heparin cofactor activity) according to Abildgaard et al. [5] us- 
ing the chromogenic substrate Chromozym TH. Anti-Xa activi- 
ty was measured according to [6] in the presence of heparin 
(anti-Xa heparin cofactor) using the substrate S2222. All values 
were expressed as a percentage of a reference plasma defined as 
100%. Crossed immunoelectrophoresis was performed accor- 
ding to [7] with or without the addition of heparin (25 U/ml) in 
the first dimension. Heparin affinity chromatography of patient 
plasma was performed using a heparin sepharose column 
(7.5 x 1 cm) and a 0.15-1.5 M NaCl gradient o elute AT111 [8]. 
2.3. Amplification of exon 6 of the ATIII gene 
Oligonucleotides (CTGCAGGTAAATGAAGAAGGCAGT 
GA) and 5’(TTACTTCTGTTCACAAACCAAAAATA) span- 
ning positions 1202-1450 within exon 6 were synthesised on an 
Applied Biosystems DNA synthesizer and used as amplification 
primers without further purification. PCRs were performed in 
100~1 reaction volumes containing 1 ,4g of genomic DNA, 
200 PM of each dNTP (dATP, dCTP, dGTP, dTTP), 100 pmol 
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of each of the amplification oligonucleotides, in 50 mM KCI, 
10 mM Tris-HCI @H 8.8), 1.5 mM MgClz, and gelatin at 
200 fig/ml. Samples were heated to 100°C for 5 min to denature 
the DNA, briefly spun and placed in a heating block at 55°C for 
2 min. 2 U Thermus aquaticus (Tag) polymerase was added to 
each sample and the tubes overlaid with 100 ~1 light mineral oil. 
Samples were subjected to 35 cycles of amplification consisting 
of a 20-s extension step at 76”C, a l-s 94°C denaturation step, 
and a l-s 55°C annealing step. On the final cycle the extension 
time was increased to 10 min. After the amplifications were 
completed, 18 ~1 of each reaction was analyzed on a 1.5% 
agarose gel containing ethidium bromide (0.5 pg/ml). 
Prior to sequencing, the amplified DNA was purified on a 
Sephadex GlOO column [9]. 
2.4. Direct sequencing of the PCR product 
A sequencing oligonucleotide 5 ‘(AGAATAAGAACATTTT 
ACTT) spanning bases 1390-1409 of the non-coding strand of 
exon 6 was synthesised as described for the amplification 
primers. Sequencing primers were purified before use on 20% 
denaturing polyacrylamide gels. Sequencing was otherwise as 
reported previously [lo]. 
3. RESULTS 
3.1. Case history 
The propositus was a 30-year-old woman who, 
at the age of 17 years, developed a deep vein throm- 
bosis (DVT) 2 months after commencing the oral 
contraceptive pill. She suffered a second spon- 
taneous DVT at age 21 and a third during her first 
pregnancy at age 29. Her mother also had recurrent 
spontaneous venous thromboses from the age of 17 
years. 
3.2. Antithrombin measurement i  plasma 
Plasma antithrombin assays (table 1) showed 
both the propositus and her mother to have abnor- 
mal heparin cofactor and progressive activity but 
normal antigenic levels. Crossed immunoelectro- 
phoresis demonstrated normal heparin affinity. 
Table 1 
Results of plasma antithrombin assays 
Antigen Inhibitory activity (n = 100%) 
With heparin Without heparin 
IIa Xa IIa 
Propositus 95 54 46 63 
Mother 98 58 50 67 
Brother 90 102 
Sister 95 105 
These findings are consistent with an abnormality 
primarily affecting inhibitory function at the reac- 
tive centre. 
3.3. Heparin sepharose chromatography 
AT111 from patient plasma behaved similarly to 
normal AT111 on heparin sepharose and was eluted 
as a single peak with 0.75 M NaCl. 
3.4. Amplification and sequencing of exon 6 
Amplification of exon 6 resulted in a single frag- 
ment of 249 base pairs (bp) (fig.1). Sequencing of 
this amplified DNA revealed two bands at 
nucleotide position 1246 (fig.2) representing the 
normal guanine (G) and the mutant cytosine (C) 
bases. The derived sequences from the anti-sense 
strand are, therefore, GCA and CCA coding for 
alanine and proline, respectively. 
A B 
271 1281 
234 
249 bp 
Fig.1. Analysis of the amplified DNA on a 1.5% agarose gel in 
1 x Tris-borate/EDTA buffer (TBE) containing ethidium 
bromide (0.5 pg/ml). The left-hand lane contains a size marker, 
3.2 fig 6X174/HaeIII, lane A 18 ~1 amplified AT111 Cambridge, 
and lane B 18 ~1 amplified control DNA. 
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A C G T reversibly move in and out of the adjacent large A 
pleated sheet. This potential movement holds the 
loop in the stressed conformation presumed 
necessary for inhibitory activity. Thus, all the in- 
hibitory members of the family have a conserved 
region, 382-385, consisting of small side-chain 
amino acids principally alanine, glycine, serine or 
threonine. Exceptions are the non-inhibitory ser- 
pins angiotensinogen and ovalbumin which have 
bulky residues (glutamic acid, valine) in this region 
and hence do not have the stressed conformation of 
other members of the family [12]. The presence of 
the imino acid proline at position 384 in antithrom- 
bin Cambridge will predictably have a similar ef- 
fect, i.e. a distortion of the base region of the reac- 
tive centre loop with a consequent loss of move- 
ment of this region and hence of inhibitory activity. 
Fig.2. Direct sequence analysis of the antisense trand of AT111 
Cambridge indicating a mutation in the gene at codon 384. 
Reading from the bottom of the gel, the sequences are com- 
plementary to the sense strand. Thus, in the normal antithrom- 
bin III gene, codon 384 which codes for alanine is CGT (GCA 
on sense strand), whilst in antithrombin Cambridge, codon 384 
which codes for proline, is GGT (CCA on sense strand). 
4. DISCUSSION 
We report here a new antithrombin variant, anti- 
thrombin Cambridge, that has normal heparin 
binding but has lost its thrombin inhibitory activi- 
ty. This variant is due to a single point mutation 
resulting in the replacement of the normal alanine 
residue at 384 by a proline. Alanine 384 is 
separated by 9 residues from the reactive centre of 
antithrombin at arginine 393. The conformation of 
this region of the antithrombin molecule is not 
known though predictions can be made from the 
crystallographic structure of another serpin, 
err-antitrypsin [l I]. This predicts that alanine 384 
will lie near the base of an exposed loop of peptide 
which has the reactive centre at its distal end. A 
feature of the proposed mechanism for the in- 
hibitory activity of the serpins is that the base of 
the reactive centre loop (i.e. residues 382-385) can 
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